Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ensituximab with Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer
NCT01834235Phase 2Terminated
- Sponsor
- Precision Biologics
- Start
- Apr 2013
- Primary completion
- Mar 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ensituximab in pancreatic adenocarcinoma (PDAC) (3 arms), sponsored by Precision Biologics. Primary endpoints: Safety and Tolerability at 28 days and Overall Survival. Started Apr 2013; status: terminated.
02
Drugs
ensituximab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01834235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01834235.